DEXWireNews

Immunic Inc Rises on trial data

NASDAQ:IMUX   Immunic, Inc.
shares are trading higher after the company reported its IMU-838 demonstrated preclinical activity against the coronavirus SARS-CoV-2 it is exploring plans for a Phase 2 clinical trial in coronavirus patients. Source seekignalpha

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our App on Google Play! dexwirenews.com/APP

2) Text Message Notifications: dexwirenews.com/SMS

3) Telegram: t.me/DEXWireNews

4) Follow Us on our Social Networks
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.